New understanding of the pathogenesis of CML; a prototype of early neoplasia by Dr Bayard Clarkson and colleagues

TO THE EDITOR
The paper published in Leukemia 1997; 11: 1404-1428, 1 provides a revised and updated version of the 'discordant maturation' theory, that was already proposed by Dr Clarkson, based on clinical, hematological, biochemical and cell culture data. I am not able to understand if the molecular findings that are reported in the paper are actually important and if they allow the conclusion that sustained brc/abl-induced phosphorylation of a number of signalling proteins, including c-kit-activated pathways, can explain the pathogenesis and the hematologic features of CML. The proposition is logical and is likely to be correct, but the puzzle is far from complete. The paper can contribute to explaining why the number of self-renewing, truly stem, Ph + cells is small, hence why immune recognition and reaction can be so important for the control of the minimal residual disease after allogeneic BMT. When we transplant a case of Ph + CML, we treat a patient with overt leukemia and a huge leukemia cell mass, apparently, but the actual number of Ph + stem cells can be so low that it is likely to be lower than that of a case of acute leukemia in socalled complete remission. That is why allogeneic BMT, and the infusion of allogeneic lymphocytes, is much more efficient in CML than in any other disease. The hypothesis that is discussed in the paper would also provide a testable model for the antileukemic effect of ␣-interferon, suggesting that ␣-interferon would not interfere with stem cell renewal, but with the expansion of committed progenitor compartments, and predicting that the therapeutic effect of ␣-interferon would be 
Response to Michele Baccarani
TO THE EDITOR
Like Dr Goldman and his colleagues, Dr Baccarani has also had enormous experience in analyzing the results of treatment of patients with CML with ␣-interferon and other modalities, and we very much appreciate his comments based on this broad perspective. Dr Baccarani raises several important questions that we did not fully address in our review which was almost entirely focused on attempting to understand the genesis of the initial chronic stage of CML.
In regard to the inevitable progression to acute leukemia, we assume all of the manifestations of the chronic phase are preceded by a substantial reduction of the phosphorylation of signalling proteins. It would be important to know the effect of ␣-interferon on the phosphorylation of the 62 kDa P-tyr protein that is extensively cited in the paper.
On the other hand, Dr Clarkson and colleagues do not help in answering at least two crucial questions. The first unanswered question concerns normal stem cells. Why do normal stem cells disappear so quickly? And why normal stem cells are maintained for so long, when ␣-interferon is administered? The second question concerns leukemic stem cells. We know that in all cases they become more leukemic, but we do not know the molecular basis and the molecular mechanisms of progression. Rapid progression to leukemia could be explained either by more events (more cell generations) in the stem cell pool or by less control of DNA duplication, or both. If Dr Clarkson's hypothesis is correct, it would explain myeloid expansion, but a low rate of stem cell renewal would not explain the rapid and fatal progression to acute leukemia.
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Cattedra di Ematologia Policlinico Universitaro Piazza S Maria della Misericordia I-33100 Udine Italy due to the 9;22 translocation, but that progression to acute leukemia with loss of ability of the cells to mature is the result of acquisition of additional genetic abnormalities, whether or not they are evident on karyotypic analysis. The reason why t(9;22) causes genetic instability and predisposes to additional genetic changes is still uncertain, although several hypotheses have been proposed (reviewed in Refs 1 and 2). Another question concerns the normal stem cells in CML: Why do they disappear so quickly and why are they maintained so long during treatment with ␣-interferon?
A consistent finding at diagnosis is that in addition to a grossly elevated leukocyte count, the cellularity of the marrow is significantly increased and there is often extramedullary myelopoiesis in the spleen; in our studies the average cellularity of the marrow in newly diagnosed patients with CML is three to four times greater than normal.
1 The majority of mar-
